Biocompatibility of functionalized boron phosphate (BPO4) nanoparticles for boron neutron capture therapy (BNCT) application

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 3, 2014, Pages 589-597

  Achilli, Cesare ^a   Grandi, Stefania ^a   Ciana, Annarita ^a   Guidetti, Gianni F ^a   Malara, Alessandro ^a   Abbonante, Vittorio ^a   Cansolino, Laura ^a,b   Tomasi, Corrado ^a,c   Balduini, Alessandra ^a   Fagnoni, Maurizio ^a   Merli, Daniele ^a   Mustarelli, Piercarlo ^a   Canobbio, Ilaria ^a   Balduini, Cesare ^a   Minetti, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c CNR   (Italy)

Author keywords

Blood cells; Boron carrier; Cancer; Erythrocytes; Folic acid; Hemolysis; Nanomaterials; Neutrophils; Platelet aggregation

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; CELLS; DRUG THERAPY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; ORGANIC ACIDS; PLATELETS; TUMORS;

BLOOD CELLS; BORON-CARRIER; CANCER; ERYTHROCYTES; FOLIC ACIDS; HEMOLYSIS; NEUTROPHILS; PLATELET AGGREGATION;

BORON;

BORON DERIVATIVE; BORON PHOSPHATE NANOPARTICLE; FOLIC ACID; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; BLOOD CELL; BLOOD COMPONENT; CELLS; CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NEUTRON CAPTURE THERAPY; NEUTROPHIL; OSTEOSARCOMA CELL; THROMBOCYTE;

BLOOD CELLS; BORON-CARRIER; CANCER; ERYTHROCYTES; FOLIC ACID; HEMOLYSIS; NANOMATERIALS; NEUTROPHILS; PLATELET AGGREGATION;

BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CELL LINE, TUMOR; FOLIC ACID; HUMANS; NANOPARTICLES; NEOPLASMS; PHOSPHATES;

EID: 84896548097     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.10.003     Document Type: Article

References (46)

1. Soloway A.H., Tjarks W., Barnum B.A., Rong F.G., Barth R.F., Codogni I.M., et al. The chemistry of neutron capture therapy. Chem Rev 1998, 98:1515-1562.
2. Hawthorne M.F., Lee M.W. A critical assessment of boron target compounds for boron neutron capture therapy. J Neurooncol 2003, 62:33-45.
3. Barth R.F. Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 2009, 67:S3-S6.
4. Lu D.R., Mehta S.C., Chen W. Selective boron drug delivery to brain tumors for boron neutron capture therapy. Adv Drug Deliv Rev 1997, 26:231-247.
5. Caruso G., Caffo M., Alafaci C., Raudino G., Cafarella D., Lucerna S., et al. Could nanoparticle systems have a role in the treatment of cerebral gliomas?. Nanomedicine: NBM 2011, 7:744-752.
6. Tiwari S.B., Amiji M.M. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006, 3:219-232.
7. Goldberg M., Langer R., Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 2007, 18:241-268.
8. Chakrabarti A., Hosmane N.S. Nanotechnology-driven chemistry of boron materials. Pure Appl Chem 2012, 84:2299-2308.
9. Zhu Y, Lin Y, Zhu YZ, Lu J, Maguire JA, Hosmane NS. Boron Drug Delivery via Encapsulated Magnetic Nanocomposites: A New Approach for BNCT in Cancer Treatment. J Nanomater 2010; [Article ID 409320].
10. Gao S., Liu X., Xu T., Ma X., Shen Z., Wu A., et al. Synthesis and Characterization of Fe10BO3/Fe3O4/SiO2 and GdFeO3/Fe3O4/SiO2: Nanocomposites of Biofunctional Materials. ChemistryOpen 2013, 2:88-92.
11. Menichetti L., De Marchi D., Calucci L., Ciofani G., Menciassi A., Forte C. Boron nitride nanotubes for boron neutron capture therapy as contrast agents in magnetic resonance imaging at 3T. Applied Radiation and Isotopes 2011, 69:1725-1727.
12. Chakrabarti A., Kuta L.M., Krise K.J., Maguire J.A., Hosmane N.S. Boron Science: New Technologies and Applications, Chapter 20 2011, CRC Press, Hoboken.
13. Nel A., Xia T., Mädler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
14. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 2010, 267:89-105.
15. Dobrovolskaia M.A., Clogston J.D., Neun B.W., Hall J.B., Patri A.K., McNeil S.E. Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett 2008, 8:2180-2187.
16. Asharani P.V., Sethu S., Vadukumpully S., Zhong S., Lim C.T., Hande M.P., et al. Investigations on the Structural Damage in Human Erythrocytes Exposed to Silver, Gold, and Platinum Nanoparticles. Adv Funct Mater 2010, 20:1233-1242.
17. Yu T., Malugin A., Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano 2011, 5:5717-5728.
18. Zhao Y., Sun X., Zhang G., Trewyn B.G., Slowing I.I., Lin V.S. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 2011, 5:1366-1375.
19. Radomski A., Jurasz P., Alonso-Escolano D., Drews M., Morandi M., Malinski T., et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005, 146:882-893.
20. Semberova J., De Paoli Lacerda S.H., Simakova O., Holada K., Gelderman M.P., Simak J. Carbon nanotubes activate blood platelets by inducing extracellular Ca2+ influx sensitive to calcium entry inhibitors. Nano Lett 2009, 9:3312-3317.
21. Bihari P., Holzer M., Praetner M., Fent J., Lerchenberger M., Reichel C.A., et al. Single-walled carbon nanotubes activate platelets and accelerate thrombus formation in the microcirculation. Toxicology 2010, 269:148-154.
22. Guidetti G.F., Consonni A., Cipolla L., Mustarelli P., Balduini C., Torti M. Nanoparticles induce platelet activation in vitro through stimulation of canonical signalling pathways. Nanomedicine: NBN 2012, 8:1329-1336.
23. Waters K.M., Masiello L.M., Zangar R.C., Tarasevich B.J., Karin N.J., Quesenberry R.D., et al. Macrophage responses to silica nanoparticles are highly conserved across particle sizes. Toxicol Sci 2009, 107:553-569.
24. Park E.J., Park K. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol Lett 2009, 184:18-25.
25. Gonçalves D.M., Chiasson S., Girard D. Activation of human neutrophils by titanium dioxide (TiO2) nanoparticles. Toxicol In Vitro 2010, 24:1002-1008.
26. Bartneck M., Keul H.A., Singh S., Czaja K., Bornemann J., Bockstaller M., et al. Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano 2010, 4:3073-3086.
27. Bartneck M., Keul H.A., Zwadlo-Klarwasser G., Groll J. Phagocytosis independent extracellular nanoparticle clearance by human immune cells. Nano Lett 2010, 10:59-63.
28. Bregoli L., Chiarini F., Gambarelli A., Sighinolfi G., Gatti A.M., Santi P., et al. Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. Toxicology 2009, 262:121-129.
29. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384.
30. Malech H.L., Gallin J.I. Current concepts: immunology. Neutrophils in human diseases. N Engl J Med 1987, 317:687-694.
31. Ciofani G., Raffa V., Menciassi A., Cuschieri A. Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy. Nanoscale Res Lett 2008, 4:113-121.
32. Yang X., Grailer J.J., Pilla S., Steeber D.A., Gong S. Tumor-Targeting, pH-Responsive, and Stable Unimolecular Micelles as Drug Nanocarriers for Targeted Cancer Therapy. Bioconjugate Chem 2010, 21:496-504.
33. Morelli C., Maris P., Sisci D., Perrotta E., Brunelli E., Perrotta I., et al. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells. Nanoscale 2011, 3:3198-3207.
34. Low P.S., Kularatne S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009, 13:256-262.
35. Ferrari C., Zonta C., Cansolino L., Clerici A.M., Gaspari A., Altieri S., et al. Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy. Appl Radiat Isot 2009, 67:S341-S344.
36. Ferrari C., Bakeine J., Ballarini F., Boninella A., Bortolussi S., Bruschi P., et al. In Vitro and In Vivo Studies of Boron Neutron Capture Therapy: Boron Uptake/Washout and Cell Death. Rad Res 2011, 175:452-462.
37. Zonta A., Prati U., Roveda R., Ferrari C., Zonta S., Clerici A.M., et al. Clinical lessons from the first applicationns of BNCT on unresectable liver metastases. J of Physics: Conf Series 2006, 41:484-495.
38. Zonta A., Pinelli T., Prati U., Riveda L., Ferrari C., Clerici A.M., et al. Extra-corporeal liver BNCT for the treatment of diffuse metastases: What was learned and what is still to be learned. Appl Radiat Isot 2009, 67:S67-S75.
39. Grandi S., Spinella A., Tomasi C., Bruni G., Fagnoni M., Merli D., et al. Synthesis and characterisation of functionalized borosilicate nanoparticles for boron neutron capture therapy applications. J Sol-gel. Sci Technol 2012, 64:358-366.
40. Greenberg A., Clesceri L.S., Eaton A.D. Standard methods for the examination of water and wastewater 1999, American Public Health Association, American Water Work Association and Water Environment Federation, Washington DC. 20th ed.
41. Beutler E., West C., Blume K.G. Removal of leukocytes and platelets from whole-blood. J Lab Clin Med 1976, 88:328-333.
42. Achilli C., Ciana A., Balduini C., Risso A., Minetti G. Application of gelatin zymography for evaluating low levels of contaminating neutrophils in red blood cell samples. Anal Biochem 2011, 409:296-297.
43. Currao M., Balduini C.L., Balduini A. High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes. PLoS One 2013, 8:e54723.
44. Li S.Q., Zhu R.R., Zhu H., Xue M., Sun X.Y., Yao S.D., et al. Nanotoxicity of TiO2 nanoparticles to erythrocyte in vitro. Food Chem Toxicol 2008, 46:3626-3631.
45. Ciana A., Achilli C., Balduini C., Minetti G. On the association of lipid rafts to the spectrin skeleton in human erythrocytes. Biochim Biophys Acta 1808, 2011:183-190.
46. Minetti G., Egée S., Mörsdorf D., Steffen P., Makhro A., Achilli C., et al. Red cell investigations: art and artefacts. Blood Rev 2013, 27:91-101.